NZ590351A - HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region - Google Patents

HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region

Info

Publication number
NZ590351A
NZ590351A NZ590351A NZ59035109A NZ590351A NZ 590351 A NZ590351 A NZ 590351A NZ 590351 A NZ590351 A NZ 590351A NZ 59035109 A NZ59035109 A NZ 59035109A NZ 590351 A NZ590351 A NZ 590351A
Authority
NZ
New Zealand
Prior art keywords
linked
regulatory region
domain
partially free
totally
Prior art date
Application number
NZ590351A
Other languages
English (en)
Inventor
Manon Couture
Louis-Philippe Vezina
Nathalie Landry
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of NZ590351A publication Critical patent/NZ590351A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
NZ590351A 2008-07-18 2009-07-15 HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region NZ590351A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8181108P 2008-07-18 2008-07-18
PCT/CA2009/001040 WO2010006452A1 (en) 2008-07-18 2009-07-15 New influenza virus immunizing epitope

Publications (1)

Publication Number Publication Date
NZ590351A true NZ590351A (en) 2012-11-30

Family

ID=41549982

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590351A NZ590351A (en) 2008-07-18 2009-07-15 HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region

Country Status (18)

Country Link
US (1) US9546375B2 (enExample)
EP (1) EP2318530B1 (enExample)
JP (1) JP5813505B2 (enExample)
KR (1) KR101745925B1 (enExample)
CN (1) CN102165062B (enExample)
AU (1) AU2009270404B2 (enExample)
CA (1) CA2730668C (enExample)
DK (1) DK2318530T3 (enExample)
ES (1) ES2593277T3 (enExample)
IL (1) IL210451A (enExample)
MX (2) MX370690B (enExample)
MY (1) MY161965A (enExample)
NZ (1) NZ590351A (enExample)
PT (1) PT2318530T (enExample)
RU (1) RU2546872C2 (enExample)
SG (1) SG192503A1 (enExample)
WO (1) WO2010006452A1 (enExample)
ZA (1) ZA201101231B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
DK2294202T3 (en) 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
KR101745925B1 (ko) 2008-07-18 2017-06-12 메디카고 인코포레이티드 신규 인플루엔자 바이러스 면역화 에피토프
SI2445928T1 (en) 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
CA2811023A1 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
WO2012047941A2 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
AU2011348160A1 (en) * 2010-12-22 2013-04-04 Novavax Inc. Modified influenza hemagglutinin proteins and uses thereof
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
US20140227322A1 (en) * 2011-06-13 2014-08-14 Medicago Inc. Rabies virus like particle production in plants
TWI700368B (zh) 2011-09-30 2020-08-01 苜蓿股份有限公司 增加植物類病毒顆粒產率
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
JP2016516415A (ja) 2013-03-28 2016-06-09 メディカゴ インコーポレイテッド 植物におけるインフルエンザウイルス様粒子の生成
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
KR102748840B1 (ko) 2016-02-03 2025-01-02 씨지 디스커버리, 인코포레이티드 이종 에피토프 및/또는 성숙 절단 부위를 갖는 인플루엔자 헤마글루티닌 조성물
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3699186A4 (en) * 2017-10-18 2021-12-15 Xiamen University H3N2 SUBTYPE INFLUENZA VIRUS HEMAGGLUTININ PROTEIN MUTANT AND USE OF IT
AU2019295495B2 (en) 2018-06-27 2025-05-22 Aramis Biotechnologies Inc. Influenza virus hemagglutinin mutants

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES ASSOCIATED WITH VIRAL GLUCOPROTEINS WITHOUT GLUCOSE.
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5312746A (en) * 1993-01-08 1994-05-17 Life Technologies, Inc. Cloning and expressing restriction endonucleases and modification methylases from caryophanon
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
GB9524350D0 (en) 1995-11-29 1996-01-31 Lynxvale Ltd Enhancer-increased gene expression in plants
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US5945326A (en) * 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
US20010006950A1 (en) * 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) * 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU1738401A (en) 1999-10-26 2001-05-08 Plant Research International B.V. Mammalian-type glycosylation in plants
CA2434364C (en) 2001-01-19 2013-03-19 The Dow Chemical Company Method for secretory production of glycoprotein having human-type sugar chain using plant cell
AU2003219745B8 (en) * 2002-02-13 2008-10-09 Wisconsin Alumni Research Foundation Signal for packaging of influenza virus vectors
EP2319935B1 (en) * 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
EP2339004B1 (en) * 2002-03-19 2015-02-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040264870A1 (en) 2002-08-20 2004-12-30 Skunes Timothy A. Optical alignment mount with height adjustment
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
AU2004235813B2 (en) 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
ES2662118T3 (es) 2005-04-29 2018-04-05 University Of Cape Town Expresión de proteínas virales en las plantas
CA2615658A1 (en) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
RU2483751C2 (ru) * 2005-10-18 2013-06-10 Новавакс, Инк. ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs)
CA2627105A1 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
EP1984405A4 (en) 2006-02-13 2010-06-30 Fraunhofer Usa Inc INFLUENZA ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
US8778353B2 (en) * 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
JP2009540801A (ja) * 2006-06-16 2009-11-26 ダウ・アグロサイエンス・エル・エル・シー トリインフルエンザ赤血球凝集素の新規なｄｎａ配列、ベクターおよびタンパク質
CN104962579A (zh) 2007-06-15 2015-10-07 麦迪卡格公司 修饰植物中的糖蛋白产生
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
IL203018A (en) 2007-07-13 2015-01-29 Medicago Inc Influenza virus-like particles containing megalotinin produced in a plant
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
KR101745925B1 (ko) 2008-07-18 2017-06-12 메디카고 인코포레이티드 신규 인플루엔자 바이러스 면역화 에피토프

Also Published As

Publication number Publication date
US20110191915A1 (en) 2011-08-04
JP5813505B2 (ja) 2015-11-17
AU2009270404B2 (en) 2015-01-29
EP2318530A4 (en) 2012-01-25
ES2593277T3 (es) 2016-12-07
DK2318530T3 (en) 2016-10-03
EP2318530B1 (en) 2016-06-22
CN102165062B (zh) 2017-09-08
IL210451A (en) 2015-04-30
WO2010006452A1 (en) 2010-01-21
ZA201101231B (en) 2011-10-26
PT2318530T (pt) 2016-09-30
MY161965A (en) 2017-05-15
CN102165062A (zh) 2011-08-24
JP2011528223A (ja) 2011-11-17
MX370690B (es) 2019-12-19
RU2011105885A (ru) 2012-08-27
HK1156969A1 (zh) 2012-06-22
IL210451A0 (en) 2011-03-31
KR101745925B1 (ko) 2017-06-12
AU2009270404A1 (en) 2010-01-21
CA2730668A1 (en) 2010-01-21
SG192503A1 (en) 2013-08-30
US9546375B2 (en) 2017-01-17
EP2318530A1 (en) 2011-05-11
MX2011000657A (es) 2011-03-21
RU2546872C2 (ru) 2015-04-10
KR20110031966A (ko) 2011-03-29
CA2730668C (en) 2020-04-28

Similar Documents

Publication Publication Date Title
NZ590144A (en) Influenza virus-like particles (vlps) comprising hemagglutinin
MY151119A (en) Duck embryonic derived stem cell lines for the production of viral vaccines
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
MX394097B (es) Producción de partículas similares a virus en plantas.
MX2010005461A (es) Variantes de glucoamilasa con propiedades alteradas.
WO2010101663A3 (en) Live attenuated influenza virus vaccines comprising microrna response elements
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
MX2015013700A (es) Produccion de particulas similares a virus de influenza en plantas.
MX2010003202A (es) Metodo para producir virus de la gripe.
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
IN2012DN03330A (enExample)
NZ606087A (en) Influenza vaccine
NZ596366A (en) Enhanced immune response in avian species
MY166220A (en) Rabies virus like particle production in plants
NZ622731A (en) Increasing virus-like particle yield in plants
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
BRPI0409871A (pt) promotores tecido-especìficos
PH12015500095B1 (en) Attenuated swine influenza vaccines and methods of making and use thereof
EP2557938A4 (en) PROTECTED ALPHA AMYLASE
MX2011002309A (es) Anticuerpos de aves especificos para virus de influenza y metodos tecnologicamente sencillos de su fabricacion y uso.
WO2007103767A3 (en) Role of microrna in plant salt tolerance
CN102399498A (zh) 粘蝇纸的粘剂
RU2008139004A (ru) Ген вакцинного искусственного белка, продуцирующий в растениях рекомбинантную мультиэпитопную вакцину на базе гемагглютинина вируса гриппа птиц
CN202857398U (zh) 一种组合花盆

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2016 BY CPA GLOBAL

Effective date: 20130704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 15 JUL 2029 BY SHELSTON IP

Effective date: 20140627

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2022 BY SHELSTON IP

Effective date: 20140627

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2019 BY SHELSTON IP

Effective date: 20140627